Novo Nordisk initiates Phase I diabetes trials of an oral GLP-1 drug
This article was originally published in Scrip
Executive Summary
Novo Nordisk has started a Phase I trial of its diabetes drug NN9924, which the company hopes could become the first oral GLP-1 analogue.